Cargando…
Efficacy and Safety of Regorafenib Monotherapy among Patients with Previously Treated Metastatic Colorectal Cancer in a Chinese Population: A Real-World Exploratory Study
BACKGROUND: Present study was condeucted to investigate the efficacy and safety of regorafenib for patients with previously treated metastatic colorectal cancer (mCRC) in a Chinese population and the prognostic implications of adverse reactions. METHODS: This retrospective study a total of 96 consec...
Autores principales: | Wang, Rui-Tao, Zhao, Yang, Wang, An-Lei, Wang, Yu-Ting, Yin, Zhong-Ping, Chen, Kai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434851/ https://www.ncbi.nlm.nih.gov/pubmed/34522132 http://dx.doi.org/10.2147/IJGM.S325545 |
Ejemplares similares
-
Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study
por: Deng, Ya-Ya, et al.
Publicado: (2023) -
Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
por: Ramaswamy, Anant, et al.
Publicado: (2019) -
Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study
por: Zhang, Song, et al.
Publicado: (2022) -
Real‐World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
por: Patel, Anuj K., et al.
Publicado: (2019) -
Efficacy and safety of raltitrexed plus S-1 versus
regorafenib in patients with refractory metastatic colorectal cancer: a
real-world propensity score matching study
por: Zhou, Yu-Wen, et al.
Publicado: (2022)